AI Article Synopsis
- - Ongoing research shows that immunotherapy for advanced ovarian cancer has limited effectiveness when used alone, but combining it with other treatments can enhance its success.
- - Biomarkers can help identify which patients are more likely to respond positively to immunotherapy, improving treatment precision; key biomarkers include factors like homologous repair deficiency and PD-L1 expression.
- - The review discusses how studying biomarkers from genomics, transcriptomics, and proteomics perspectives can guide effective immunotherapy strategies for ovarian cancer in the future.
Article Abstract
The ongoing research on the role of immunotherapy in advanced ovarian cancer (OC) and current clinical trials indicate that patients shown limited response to immune checkpoint inhibitor (ICI) monotherapy. When combined with other treatments or drugs, the efficacy of immunotherapy will be significantly improved. Biomarkers can be used to identify patients with better responses, thereby improving the precision and efficacy of immunotherapy. Key biomarkers for advanced OC include homologous repair deficiency, programmed death-ligand (PD-L) 1 expression, chemokines, and tumor infiltrating lymphocytes. These biomarkers could be applied in the future to select the most suitable patient populations. This review comprehensively examines the research and development of biomarkers in OC immunotherapy from three omics perspectives: genomics, transcriptomics, and proteomics, which may provide guidance for the effectiveness of OC immunotherapy strategies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10637-024-01478-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!